Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Arcellx

Biotech & Life Sciences · Gaithersburg, United States · Founded 2015 · IPO 2022 Unicorn

Intelligent and adaptive cell therapies to treat the complexity of human disease

Valuation
$6.33B
Market cap · May/2026
Revenue
$22M
Latest reported FY
Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

23 investors on Arcellx's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage
Novo Ventures
NEA
Series B+ 21 investors entered at this stage
Soleus Capital
CaaS Capital Management
Surveyor Capital
LG Technology Ventures
Quan Capital
Suvretta Capital Management
Asymmetry
Cambrian BioPharma
Clough Capital Partners
Takeda Ventures
CAM Capital
Adage Capital
Samsara BioCapital
SR One
Mirae Asset Capital
Quan Capital
Novo Holdings
Sixty Degree Capital
Terra Magnum Capital Partners
Aju IB Investment
Mirae Asset Venture Investment

Global footprint

Where Arcellx has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown
Web traffic by country
12K monthly visits
across markets
🇺🇸 United States58.3%
🇮🇳 India14.2%
🇨🇦 Canada10%
🇯🇵 Japan8.3%
🇵🇭 Philippines5.8%
Top 5 markets shown

Market sentiment

What the market is saying about Arcellx

An AI-synthesized read of the highest-engagement posts about Arcellx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Arcellx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles